Boehringer Ingelheim's Combivent
Company is understood to have received a lengthy "not approvable" letter from FDA Feb. 23 for its ipratropium bromide/albuterol sulfate combination product. FDA's concerns regarding the Combivent inhalation aerosol NDA apparently include production and GMP issues, as well as the need for additional safety data on coadminstration of the two drug components. Boehringer Ingelheim filed its NDA (20-291) for the bronchodilator May 23, 1993 for the treatment of bronchospasms associated with chronic obstructive pulmonary disease
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth